As of 2026-04-02, the Relative Valuation of BioCryst Pharmaceuticals Inc (BCRX) is 20.46 USD. This relative valuation is based on P/E multiples. With the latest stock price at 9.38 USD, the upside of BioCryst Pharmaceuticals Inc based on Relative Valuation is 118.1%.
The range of the Relative Valuation is 16.93 - 23.27 USD.
| Range | Selected | |
| Trailing P/E multiples | 17.0x - 21.3x | 19.4x |
| Forward P/E multiples | 15.4x - 21.2x | 18.7x |
| Fair Price | 16.93 - 23.27 | 20.46 |
| Upside | 80.5% - 148.0% | 118.1% |
| Date | P/E |
| 2026-04-01 | 8.92 |
| 2026-03-31 | 9.05 |
| 2026-03-30 | 8.98 |
| 2026-03-27 | 8.87 |
| 2026-03-26 | 9.09 |
| 2026-03-25 | 8.93 |
| 2026-03-24 | 9.18 |
| 2026-03-23 | 9.31 |
| 2026-03-20 | 9.22 |
| 2026-03-19 | 9.32 |
| 2026-03-18 | 8.71 |
| 2026-03-17 | 8.75 |
| 2026-03-16 | 8.84 |
| 2026-03-13 | 7.81 |
| 2026-03-12 | 7.97 |
| 2026-03-11 | 8.07 |
| 2026-03-10 | 8.32 |
| 2026-03-09 | 8.19 |
| 2026-03-06 | 8.06 |
| 2026-03-05 | 8.08 |
| 2026-03-04 | 8.15 |
| 2026-03-03 | 8.26 |
| 2026-03-02 | 8.20 |
| 2026-02-27 | 8.32 |
| 2026-02-26 | 7.51 |
| 2026-02-25 | 7.18 |
| 2026-02-24 | 7.23 |
| 2026-02-23 | 7.20 |
| 2026-02-20 | 7.08 |
| 2026-02-19 | 7.11 |
| 2026-02-18 | 6.90 |
| 2026-02-17 | 6.61 |
| 2026-02-13 | 6.43 |
| 2026-02-12 | 6.46 |
| 2026-02-11 | 6.50 |
| 2026-02-10 | 6.23 |
| 2026-02-09 | 5.99 |
| 2026-02-06 | 6.06 |
| 2026-02-05 | 5.93 |
| 2026-02-04 | 6.10 |
| 2026-02-03 | 6.37 |
| 2026-02-02 | 6.30 |
| 2026-01-30 | 6.25 |
| 2026-01-29 | 6.34 |
| 2026-01-28 | 6.33 |
| 2026-01-27 | 6.43 |
| 2026-01-26 | 6.52 |
| 2026-01-23 | 6.45 |
| 2026-01-22 | 6.42 |
| 2026-01-21 | 6.39 |